VanEck Associates’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-19,760
| Closed | -$66K | – | 1034 |
|
|
2019
Q4 | $66K | Buy |
19,760
+1,977
| +11% | +$6.29K | ﹤0.01% | 869 |
|
|
2019
Q3 | $54K | Buy |
17,783
+59
| +0.3% | +$166 | ﹤0.01% | 791 |
|
|
2019
Q2 | $42K | Sell |
17,724
-2,499
| -12% | -$7.47K | ﹤0.01% | 789 |
|
|
2019
Q1 | $76K | Buy |
20,223
+471
| +2% | +$1.76K | ﹤0.01% | 766 |
|
|
2018
Q4 | $71K | Buy |
19,752
+8,474
| +75% | +$36.9K | ﹤0.01% | 742 |
|
|
2018
Q3 | $65K | Buy |
11,278
+646
| +6% | +$3.7K | ﹤0.01% | 751 |
|
|
2018
Q2 | $53K | Buy |
10,632
+2,057
| +24% | +$10.6K | ﹤0.01% | 793 |
|
|
2018
Q1 | $44K | Buy |
8,575
+572
| +7% | +$3.44K | ﹤0.01% | 708 |
|
|
2017
Q4 | $48K | Sell |
8,003
-3,348
| -29% | -$20.1K | ﹤0.01% | 699 |
|
|
2017
Q3 | $63K | Buy |
11,351
+507
| +5% | +$2.62K | ﹤0.01% | 682 |
|
|
2017
Q2 | $50K | Sell |
10,844
-257
| -2% | -$1.15K | ﹤0.01% | 723 |
|
|
2017
Q1 | $55K | Hold |
11,101
| – | – | ﹤0.01% | 849 |
|
|
2016
Q4 | $123K | Sell |
11,101
-3,730
| -25% | -$35.1K | ﹤0.01% | 710 |
|
|
2016
Q3 | $137K | Buy |
14,831
+55
| +0.4% | +$460 | ﹤0.01% | 692 |
|
|
2016
Q2 | $94K | Sell |
14,776
-426
| -3% | -$2.83K | ﹤0.01% | 695 |
|
|
2016
Q1 | $99K | Buy |
15,202
+88
| +0.6% | +$567 | ﹤0.01% | 675 |
|
|
2015
Q4 | $123K | Buy |
15,114
+2,213
| +17% | +$16.5K | ﹤0.01% | 602 |
|
|
2015
Q3 | $95K | Buy |
+12,901
| New | +$131K | ﹤0.01% | 629 |
|
VanEck Associates's FOMX Position: Q1 2020 in Review
VanEck Associates sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 19,760 shares — an estimated $66K sold.
VanEck Associates first reported a position in FOMX in Q3 2015 and held it in 18 quarters. The position peaked at $137K in Q3 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- VanEck Associates reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- VanEck Associates sold 19,760 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $66K.
- VanEck Associates first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2015 and held it in 18 quarters.
- VanEck Associates's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $137K in Q3 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on VanEck Associates's 13F filing for Q1 2020, filed 12 May 2020.